Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors.

ABSTRACT: SARS-CoV-2 encodes two viral cysteine proteases, the main protease (M^pro) and the papain-like protease (PL^pro), both of which are validated antiviral drug targets. PL^pro is involved in the cleavage of viral polyproteins as well as immune modulation by removing ubiquitin and interferon-stimulated gene product 15 (ISG15) from host proteins. Therefore, targeting PL^pro might be a two-pronged approach. Several compounds including YM155, cryptotanshinone, tanshinone I, dihydrotanshinone I, tanshinone IIA, SJB2-043, 6-thioguanine, and 6-mercaptopurine were recently identified as SARS-CoV-2 PL^pro inhibitors through high-throughput screenings. In this study, we aim to validate/invalidate the reported PL^pro inhibitors using a combinat

SUBMITTER: Ma C 

PROVIDER: S-EPMC8806001 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature